AURO LABORATORIES LTD.

Auro Laboratories Limited has announced its Unaudited Financial Results for the quarter ended June 30, 2026. The Board of Directors approved these results, which were recommended by the Audit Committee. The company will publish the results in newspapers in due course. The financial results were prepared in accordance with Indian Accounting Standards (IndAS 34) and SEBI (LODR) Regulations, 2015. The company operates in a single segment, Pharmaceuticals.

Auro Laboratories Limited announced the outcome of its Board Meeting held on August 14, 2026. The Board approved the Unaudited Financial Results for the quarter ended June 30, 2026. The results were recommended by the Audit Committee and have been prepared in accordance with Indian Accounting Standards (IndAS 34). The company operates in a single segment, Pharmaceuticals. The financial results will be published in newspapers in due course.

Auro Laboratories Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, along with the limited review report. Additionally, the trading window for designated persons will remain closed until 48 hours after the board meeting concludes, in line with the company's insider trading code of conduct.

Auro Laboratories Ltd has informed shareholders about the availability of its Annual Report for FY 2025-2026. In compliance with SEBI regulations, a letter containing the web-link and exact path to access the report on the company's website has been sent to members who have not registered their email addresses. The company also reminded shareholders to update their KYC details and dematerialize physical securities as per SEBI's master circular. The 37th Annual General Meeting is scheduled for August 11, 2026, via Video Conferencing.

Auro Laboratories Ltd has submitted its Annual Report for the Financial Year 2025-2026, in compliance with Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The submission includes the Notice for the 37th Annual General Meeting (AGM), which is scheduled to be held on Tuesday, August 11, 2026, at 11:30 AM (IST) through Video Conferencing/Other Audio-Visual Means. The key business items for the AGM include the adoption of the audited financial statements for the year ended March 31, 2026, and the re-appointment of Mr. Kiran Kulkarni as a director who retires by rotation. The Annual Report and Notice are also accessible on the company's website.

Auro Laboratories Ltd has announced its 37th Annual General Meeting (AGM) will be held on August 11, 2026, at 11:30 a.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in compliance with regulatory circulars. The company is providing members with the facility for e-voting on all resolutions. The AGM will cover ordinary business, including the adoption of audited financial statements for the fiscal year 2025-26 and the re-appointment of a director retiring by rotation.

Auro Laboratories Limited announced the re-appointment of Mr. Kiran Suresh Kulkarni as a Whole Time Director for a term of three years, effective May 24, 2027, to May 23, 2030. This decision was made based on the recommendations of the Nomination and Remuneration Committee during a Board of Directors meeting held on June 30, 2026. The re-appointment is subject to shareholder approval at the upcoming Annual General Meeting. Mr. Kulkarni has over 25 years of experience in API manufacturing's QC/QA departments and oversees quality control and general management at the company's manufacturing facility. He is not debarred from holding directorship by any authority. The company also scheduled its 37th Annual General Meeting for August 11, 2026.

Auro Laboratories Limited's Board of Directors met on June 30, 2026, to approve the re-appointment of Mr. Kiran Suresh Kulkarni as Whole Time Director for a term of three years, effective May 24, 2027, to May 23, 2030. This re-appointment is subject to shareholder approval at the upcoming Annual General Meeting. The Board also scheduled the 37th Annual General Meeting for August 11, 2026, to be conducted via Video-Conferencing and Other Audio-Visual Means.

Auro Laboratories Limited has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 01, 2026, and applies to all connected/designated persons and their immediate relatives. The purpose of this measure is to facilitate the consideration of the un-audited financial results for the quarter ended June 30, 2026. The trading window is set to reopen 48 hours after the aforementioned financial results are made generally available to the public. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Auro Laboratories Ltd has appointed Nitesh Bohra as Chief Financial Officer, effective May 29, 2026. The company also appointed B.L. Dasharda & Associates as Tax Auditors and Kuntal Pancholi as Internal Auditor for FY 2026-27. Additionally, Poddar & Co. has been re-appointed as Cost Auditors for FY 2026-27. The board approved the audited financial results for the quarter and year ended March 31, 2026.